Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Biocon included in S&P Global Sustainability Yearbook 2024

Sustainability is integral to Biocon's business purpose

Biocon Biologics recognized as an Asia IP Elite for 2023

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

USFDA inspection at Biocon Biologics' manufacturing facility in Johor, Malaysia

Biocon names Peter Bains as Group CEO

Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.

Serum & Biocon Biologics agree to restructure equity investment

Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics